[
  {
    "ts": null,
    "headline": "Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline",
    "summary": "NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.",
    "url": "https://finnhub.io/api/news?id=dd6df03f52cfc3d38f9944721c66103bd4233ebf80c24efe99ef48d9d36950b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772208840,
      "headline": "Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline",
      "id": 139254535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.",
      "url": "https://finnhub.io/api/news?id=dd6df03f52cfc3d38f9944721c66103bd4233ebf80c24efe99ef48d9d36950b3"
    }
  },
  {
    "ts": null,
    "headline": "Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment",
    "summary": "Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children Paris and Tarryt",
    "url": "https://finnhub.io/api/news?id=aa9a6da1a74e23055e321171160368813e1bf0da6fc33cff6cda2797ec254514",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772193780,
      "headline": "Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment",
      "id": 139247357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children Paris and Tarryt",
      "url": "https://finnhub.io/api/news?id=aa9a6da1a74e23055e321171160368813e1bf0da6fc33cff6cda2797ec254514"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment",
    "summary": "If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Com",
    "url": "https://finnhub.io/api/news?id=03919d0c8ed76c3717c17956028b210f18016f0f8341f0e177899e0aea13e051",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772193600,
      "headline": "Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment",
      "id": 139247358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Com",
      "url": "https://finnhub.io/api/news?id=03919d0c8ed76c3717c17956028b210f18016f0f8341f0e177899e0aea13e051"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron And Sanofi Say European Medicines Agency's CHMP Adopts Positive Opinion Recommending Approval Of Dupixent In EU For Treatment Of Chronic Spontaneous Urticaria",
    "summary": "If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatmentCSU is a chronic skin disease",
    "url": "https://finnhub.io/api/news?id=748e5ee1e629fcb5e3125da9e7e1efa2ff3acaf25655c52d6ef710338bbf28da",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772179647,
      "headline": "Regeneron And Sanofi Say European Medicines Agency's CHMP Adopts Positive Opinion Recommending Approval Of Dupixent In EU For Treatment Of Chronic Spontaneous Urticaria",
      "id": 139247653,
      "image": "",
      "related": "REGN",
      "source": "Benzinga",
      "summary": "If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatmentCSU is a chronic skin disease",
      "url": "https://finnhub.io/api/news?id=748e5ee1e629fcb5e3125da9e7e1efa2ff3acaf25655c52d6ef710338bbf28da"
    }
  },
  {
    "ts": null,
    "headline": "Why Dupixent Keeps Regeneron A Top Big Pharma Pick",
    "summary": "Why Dupixent Keeps Regeneron A Top Big Pharma Pick",
    "url": "https://finnhub.io/api/news?id=ee5caa92701aecc77a5d035612e8dfbeac6d90daceaff1b22ffc87bbb167a7c4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772179200,
      "headline": "Why Dupixent Keeps Regeneron A Top Big Pharma Pick",
      "id": 139246428,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ee5caa92701aecc77a5d035612e8dfbeac6d90daceaff1b22ffc87bbb167a7c4"
    }
  },
  {
    "ts": null,
    "headline": "OPKO Health Q4 Earnings Call Highlights",
    "summary": "OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc",
    "url": "https://finnhub.io/api/news?id=de3bc70686768dfe5f9e5efa067f9c6598800e9e6e5498aafc68873d9e89375f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772172776,
      "headline": "OPKO Health Q4 Earnings Call Highlights",
      "id": 139244673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc",
      "url": "https://finnhub.io/api/news?id=de3bc70686768dfe5f9e5efa067f9c6598800e9e6e5498aafc68873d9e89375f"
    }
  },
  {
    "ts": null,
    "headline": "OPKO Health Inc (OPK) Q4 2025 Earnings Call Highlights: Strategic Divestitures and Promising ...",
    "summary": "Despite a challenging quarter, OPKO Health Inc (OPK) focuses on core strengths and strategic partnerships to drive future profitability.",
    "url": "https://finnhub.io/api/news?id=1b566d3a4461b793be00c3d0aa3cecf2bc1dabc1a8b09765b6ba99f6d5ce7b9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772168785,
      "headline": "OPKO Health Inc (OPK) Q4 2025 Earnings Call Highlights: Strategic Divestitures and Promising ...",
      "id": 139243856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Despite a challenging quarter, OPKO Health Inc (OPK) focuses on core strengths and strategic partnerships to drive future profitability.",
      "url": "https://finnhub.io/api/news?id=1b566d3a4461b793be00c3d0aa3cecf2bc1dabc1a8b09765b6ba99f6d5ce7b9f"
    }
  },
  {
    "ts": null,
    "headline": "Ionis Pharmaceuticals: Digesting Recent Events",
    "summary": "Ionis Pharmaceuticals: Digesting Recent Events",
    "url": "https://finnhub.io/api/news?id=b48be207fbdc717ae55d144e3d4bbfa032cd44e3cc77403d05860d0db3a3e855",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772160856,
      "headline": "Ionis Pharmaceuticals: Digesting Recent Events",
      "id": 139244654,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b48be207fbdc717ae55d144e3d4bbfa032cd44e3cc77403d05860d0db3a3e855"
    }
  }
]